NCT02953678 - A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

August 14, 2019

Conditions

Graft-versus-host Disease (GVHD)

Interventions

DRUG

Ruxolitinib

DRUG

Prednisone or methylprednisolone

Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.

Trial Locations (38)

10022

New York

10065

New York

14642

Rochester

15224

Pittsburgh

15232

Pittsburgh

19104

Philadelphia

19107

Philadelphia

26506

Morgantown

28204

Charlotte

30322

Atlanta

31010

Duarte

32610

Gainesville

33136

Miami

33612

Tampa

37203

Nashville

37232

Nashville

44195

Cleveland

45242

Cincinnati

49503

Grand Rapids

53226

Milwaukee

53705

Madison

55455

Minneapolis

60611

Chicago

60637

Chicago

63110

St Louis

75246

Dallas

78229

San Antonio

80218

Denver

84112

Salt Lake City

85719

Tucson

90033

Los Angeles

90095

Los Angeles

92903

La Jolla

94306

Stanford

98109

Seattle

40536-0293

Lexington

02114

Boston

07601

Hackensack